[Imipramine in the therapy of schizophrenic psychoses].
Imipramin causes the transmitter at synapses containing catechol amine to remain receptive for a longer time. This leads to an ergotropic dissimilation of the required value and works to prevent parkinsonism; autism is among the main symptoms. It produces dynamic expansion, directs agressive impulses outwards, increases pride, concentration and suspiction. It can set reticent schizophrenic developments in motion. The therapeutic advantage lies in the patient being enabled to adapt himself to existing conditions or achieve this therapeutic guidance.
D000328:Adult; D001321:Autistic Disorder / Q000188:drug therapy; D001714:Bipolar Disorder / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*; D012917:Social Adjustment; D014149:Tranquilizing Agents / Q000627:therapeutic use
D014149:Tranquilizing Agents; D007099:Imipramine
Imipramin in der Therapie schizophrener Psychosen.